Skip to main content

06-23-2017 | Pregnancy | Review | Article

Metabolomics of Diabetes in Pregnancy

Journal: Current Diabetes Reports

Authors: Carolyn F. McCabe, Wei Perng

Publisher: Springer US


Purpose of review

The purpose of this review is to describe ways in which metabolomics may enhance understanding of gestational diabetes mellitus (GDM) etiology and refine current diagnostic criteria.

Recent findings

Current clinical recommendations suggest screening for GDM between 24 and 28 of gestational weeks using an oral glucose tolerance test. Despite this consensus, there are discrepancies regarding the exact criteria for GDM diagnosis. Further, emerging evidence has unveiled heterogeneous physiological pathways underlying GDM—specifically, GDM with defective insulin secretion vs. sensitivity—that have important implications for disease diagnosis and management.


The objectives of this review are threefold. First, we seek to provide a brief summary of current knowledge regarding GDM pathophysiology. Next, we describe the potential role of metabolomics to refine and improve the prediction, screening, and diagnosis of GDM. Finally, we propose ways in which metabolomics may eventually impact clinical care and risk assessment for GDM and its comorbidities.
American Diabetes Association, et al. Diabetes Care. 2004;27(Suppl 1):S88–90.
DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis. 2014;11:E104. CrossRefPubMedPubMedCentral
Bardenheier BH, Imperatore G, Gilboa SM, Geiss LS, Saydah SH, Devlin HM, et al. Trends in gestational diabetes among hospital deliveries in 19 U.S. States, 2000–2010. Am J Prev Med. 2015;49:12–9. CrossRefPubMedPubMedCentral
Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004. p. 103–13.
Hartmann P, Cregan M. Lactogenesis and the effects of insulin-dependent diabetes mellitus and prematurity. J Nutr Am Soc Nutr. 2001;131:3016S–20S.
Harreiter J, Dovjak G, Kautzky-Willer A. Gestational diabetes mellitus and cardiovascular risk after pregnancy. Womens Health (Lond Engl). 2014;10:91–108. CrossRef
Durnwald C. Gestational diabetes: linking epidemiology, excessive gestational weight gain, adverse pregnancy outcomes, and future metabolic syndrome. Semin Perinatol. 2015. p. 254–8.
Burlina S, Dalfrà MG, Chilelli NC, Lapolla A. Gestational diabetes mellitus and future cardiovascular risk: an update. Int J Endocrinol. 2016;2016:1–6. CrossRef
Mohammadbeigi A, Farhadifar F, Soufi Zadeh N, Mohammadsalehi N, Rezaiee M, Aghaei M. Fetal macrosomia: risk factors, maternal, and perinatal outcomes. Ann Med Heal Sci Re. Medknow Publications. 2013;3:546–50. CrossRef
Hedderson MM, Ferrara A, Sacks DA. Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Obstet Gynecol. 2003;102:850–6. PubMed
Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obs. Gynecol. 1991;165:1667–72. CrossRef
Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obs Gynecol. 1999;180:903–16. CrossRef
Buchanan TA. Metabolic changes during normal and diabetic pregnancy. In: Reece E, Coustan D, editors. Diabetes Mellit. Pregnancy. New York: Churchill Livingstone; 1995. p. 59–77.
Sivan E, Chen X, Homko CJ, Reece EA, Boden G. Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care. 1997;20:1470–5. CrossRefPubMed
Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol. 1993;264:E60–7. PubMed
Powe CE, Allard C, Battista M-C, Doyon M, Bouchard L, Ecker JL, et al. Heterogeneous contribution of insulin sensitivity and secretion defects to gestational diabetes mellitus: table 1. Diabetes Care. 2016;39:1052–5. CrossRefPubMedPubMedCentral
Stumvoll M, Van Haeften T, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001;24:796–7. CrossRefPubMed
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23:295–301. CrossRefPubMed
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70. CrossRefPubMed
McIntyre HD, Metzger BE, Coustan DR, Dyer AR, Hadden DR, Hod M, et al. Counterpoint: establishing consensus in the diagnosis of GDM following the HAPO study. Curr Diab Rep. 2014; p. 497.
Long H, Cundy T. Establishing consensus in the diagnosis of gestational diabetes following HAPO: where do we stand? Curr. Diab. Rep. 2013;13:43–50. CrossRefPubMed
Huynh J, Xiong G, Bentley-Lewis R. A systematic review of metabolite profiling in gestational diabetes mellitus. Diabetologia. 2014;57:2453–64. CrossRefPubMedPubMedCentral
Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 2011;40:387–426. CrossRefPubMed
De Simone C V., Gaba P, Tri J, Syed F, Noheria A, Asirvatham SJ. A review of the relevant embryology, pathohistology, and anatomy of the left atrial appendage for the invasive cardiac electrophysiologist. J. Atr. Fibrillation. 2015. p. 81–7.
Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012;Chapter 30:Unit 30.2.1-24.
Dani C, Bresci C, Berti E, Ottanelli S, Mello G, Mecacci F, et al. Metabolomic profile of term infants of gestational diabetic mothers. J. Matern. Fetal. Neonatal Med. 2014;27:537–42. CrossRefPubMed
Chen X, Scholl TO, Leskiw M, Savaille J, Stein TP. Differences in maternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes Care. 2010;33:2049–54. CrossRefPubMedPubMedCentral
Scholtens DM, Muehlbauer MJ, Daya NR, Stevens RD, Dyer AR, Lowe LP, et al. Metabolomics reveals broad-scale metabolic perturbations in hyperglycemic mothers during pregnancy. Diabetes Care. 2013;37:158 LP–166. CrossRef
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448–53. CrossRefPubMedPubMedCentral
Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648–55. CrossRefPubMedPubMedCentral
• Scholtens DM, Bain JR, Reisetter AC, Muehlbauer MJ, Nodzenski M, Stevens RD, et al. Metabolic networks and metabolites underlie associations between maternal glucose during pregnancy and newborn size at birth. Diabetes. 2016;65:2039–50. This study provides a detailed characterization of metabolites quantified from maternal serum collected in the fasting state and at 1 hour following an oral glucose challenge test (OGTT) at ~28 weeks gestation with respect to newborn birth weight and adiposity among 400 mother-infant pairs in the Hyperglycemia and Adverse Pregnancy Outcomes Study (HAPO). CrossRefPubMedPubMedCentral
Sachse D, Sletner L, Mørkrid K, Jenum AK, Birkeland KI, Rise F, et al. Metabolic changes in urine during and after pregnancy in a large, multiethnic population-based cohort study of gestational diabetes. PLoS One. 2012;7:e52399. CrossRefPubMedPubMedCentral
Klein MS, Shearer J. Metabolomics and type 2 diabetes: translating basic research into clinical application. J Diabetes Res. Hindawi Publishing Corporation; 2016. p. 1–10.
Gieger C, Geistlinger L, Altmaier E, De Angelis MH, Kronenberg F, Meitinger T, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4
Altmaier E, Ramsay SL, Graber A, Mewes H-W, Weinberger KM, Suhre K. Bioinformatics analysis of targeted metabolomics—uncovering old and new tales of diabetic mice under medication. Endocrinology. 2008;149:3478–89. CrossRefPubMed
Kousta E, Ellard S, Allen LIS, Saker PJ, Huxtable SJ, Hattersley AT, et al. Glucokinase mutations in a phenotypically selected multiethnic group of women with a history of gestational diabetes [1]. Diabet Med. Blackwell Science Ltd; 2001. p. 683–4.
Chen Y, Liao WX, Roy AC, Loganath A, Ng SC. Mitochondrial gene mutations in gestational diabetes mellitus. Diabetes Res. Clin. Pr. 2000;48:29–35. CrossRef
Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn. 2011;31:135–41. CrossRefPubMed
Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care. 2003;26:819–24. CrossRefPubMed
Pinto J, Barros AS, Domingues MRM, Goodfellow BJ, Galhano E, Pita C, et al. Following healthy pregnancy by NMR metabolomics of plasma and correlation to urine. J Proteome Res. 2015;14.
Bentley-Lewis R, Huynh J, Xiong G, Lee H, Wenger J, Clish C, et al. Metabolomic profiling in the prediction of gestational diabetes mellitus. Diabetologia. 2015;58:1329–32. CrossRefPubMedPubMedCentral
Nevalainen J, Sairanen M, Appelblom H, Gissler M, Timonen S, Ryynänen M. First-trimester maternal serum amino acids and acylcarnitines are significant predictors of gestational diabetes. Rev Diabet Stud. 2016;13:236–45. CrossRefPubMed
Enquobahrie DA, Denis M, Tadesse MG, Gelaye B, Ressom HW, Williams MA. Maternal early pregnancy serum metabolites and risk of gestational diabetes mellitus. J Clin Endocrinol Metab. The Endocrine Society. 2015;100:4348–56. CrossRefPubMedPubMedCentral
de Seymour JV, Conlon CA, Sulek K, Villas Bôas SG, McCowan LME, Kenny LC, et al. Early pregnancy metabolite profiling discovers a potential biomarker for the subsequent development of gestational diabetes mellitus. Acta Diabetol. 2014;51:887–90. CrossRefPubMed
Graca G, Duarte IF, Barros AS, Goodfellow BJ, Diaz SO, Pinto J, et al. Impact of prenatal disorders on the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J Proteome Res. 2010;9:6016–24. CrossRefPubMed
Diaz SO, Pinto J, Graça G, Duarte IF, Barros AS, Galhano E, et al. Metabolic biomarkers of prenatal disorders: an exploratory NMR metabonomics study of second trimester maternal urine and blood plasma. J Proteome Res. 2011;10:3732–42. CrossRefPubMed
Graça G, Goodfellow BJ, Barros AS, Diaz S, Duarte IF, Spagou K, et al. UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers. Mol Biosyst. 2012;8:1243–54. CrossRefPubMed
Diaz SO, Barros AS, Goodfellow BJ, Duarte IF, Galhano E, Pita C, et al. Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res. 2013;12:2946–57. CrossRefPubMed
Pinto J, Almeida LM, Martins AS, Duarte D, Barros AS, Galhano E, et al. Prediction of gestational diabetes through NMR metabolomics of maternal blood. J Proteome Res. American Chemical Society. 2015;14:2696–706. CrossRefPubMed
Dudzik D, Zorawski M, Skotnicki M, Zarzycki W, Kozlowska G, Bibik-Malinowska K, et al. Metabolic fingerprint of gestational diabetes mellitus. J. Proteomics. 2014;103:57–71. CrossRefPubMed
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002. p. 1862–8.
Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30.
• Allalou A, Nalla A, Prentice KJ, Liu Y, Zhang M, Dai FF, et al. A predictive metabolic signature for the transition from gestational diabetes mellitus to type 2 diabetes. Diabetes. 2016;65:2529–39. This study, carried out among 1,010 women who were diagnosed with gestational diabetes during pregnancy, identified 21 metabolites in fasting blood collected at 6-9 weeks postpartum that predict development of type 2 diabetes within the next 2-4 years. CrossRefPubMed
Hajduk J, Klupczynska A, Dereziński P, Matysiak J, Kokot P, Nowak DM, et al. A combined metabolomic and proteomic analysis of gestational diabetes mellitus. Int J Mol Sci. Multidisciplinary Digital Publishing Institute (MDPI). 2015;16:30034–45. CrossRefPubMedPubMedCentral
Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for biomarker discovery: moving to the clinic. Biomed Res Int. Hindawi Publishing Corporation. 2015;2015:1–6.
Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 1998;15:539–53.
American Diabetes Associate. Standards of medical care in diabetes—2012. Diabetes Care. 2012. p. S11–63.
International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care. 2010;33:676 LP-682.
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Int J Gynecol Obstet. 2002;78:69–77.